Stay updated on Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial

Sign up to get notified when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.3.4 instead of v3.3.3. This is a minor version-label update that does not alter trial information or how users interact with the page.
    Difference
    0.0%
    Check dated 2026-01-14T01:18:09.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    Locations are now presented under a single 'Locations' heading, and the state-specific site details (California, Florida, Georgia, Maryland) have been removed.
    Difference
    0.5%
    Check dated 2025-12-23T08:49:00.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    Revision: v3.3.2 added and v3.3.1 removed as a minor site metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-12-01T17:22:17.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    PubMed publications note updated to state items are automatically filled from PubMed, and the revision label changed from v3.2.0 to v3.3.1.
    Difference
    0.1%
    Check dated 2025-11-24T14:36:09.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The banner notice about government funding and NIH operating status at the top of the page was removed. This does not affect the study details or eligibility information. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-17T06:47:52.000Z thumbnail image
  8. Check
    75 days ago
    Change Detected
    Summary
    No significant additions or deletions were detected in the core study information; the page’s title, identifiers, conditions, eligibility criteria, interventions, and outcomes appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T01:16:50.000Z thumbnail image

Stay in the know with updates to Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.